What @CUHKMedicine has built is nothing short of extraordinary A true powerhouse of innovation where every conversation challenges the status quo Their ambition is contagious. The sky is the limit for this team @jteoh_hk

@CUHKMedicine urology symposium starting strong with RCC IVC thrombus approaches shout out to @CleClinicUro and our very own Novick classification. Discussing minimizing need for sternotomy via IO/ TKI, endovascular approaches in level 4

@peterchiu_uro @jteoh_hk @steffiyuen are top notch hosts sharing their home with us. Lots of laughs , incredible amount of food 🥘 and unforgettable memories ! We miss you already @CUHKMedicine @Tilki_De

So great to see @wandering_gu as a candidate for the @ASCO Board and strongly support him! A thoughtful, forward-thinking leader whose insights and perspectives I have always valued. His commitment to advancing cancer care is exactly the kind of leadership ASCO needs. And a great guy 😊 You have my vote Todd! @UroDocAsh @SpiessPhilippe @RuchikaTalwarMD @AdityaBagrodia @SimaPorten @siadaneshmand Please vote asco.org/about-asco/asco-ove…

Are you interested in prostate pathology? Join us at ASCP 2026! #ASCPxCAPACP @ASCP_Chicago @Williamson_SR

We are grateful to all the distinguished faculty who made this innovations meeting outstanding! @CleClinicUro

@CleClinicUro is busy today .. two incredible symposiums Single Port upstairs and Confocal Intraoperative Pathology downstairs @samantree @JaneNguyen44

Meet the experts in Single Port robotic Surgery from all over the country at Cleveland Clinic Annual Symposium! @CleClinicUro @CleClinicNews

Honored to host the great Dr. Bud Burnett of @brady_urology for our @CleClinicUro Men’s Health Visiting Professor lecture series. Bud gave a highly impactful lecture on his work in priapism and ED pathophysiology to our urology and hematology teams from across Ohio and @CCAD.

The largest robotic course dedicated to single port robotic surgery @CleClinicUro !

Long-term oncologic outcomes of patients with grade group 1 #ProstateCancer and pT3a disease on final pathology. In 40 men with centrally confirmed Grade Group 1 prostate cancer and pT3a disease, none developed metastases or died of prostate cancer. Adverse histology, not stage alone, drives clinically meaningful risk. #AuthorCommentary on UroToday > bit.ly/4hJBXDF @JaneNguyen44 @ZSchwen @MWatfa26 @CleClinicUro @pcan_journal

Check our latest review article on #precisiondiagnostics in #genitourinarycancer! @GU_Path_Society @IntSocUropath @IPOPorto @ICBAS_UPorto @ESP_Pathology @Uroweb tandfonline.com/doi/full/10.… #pathtwitter

Come learn how @TunaBeksac delivers cutting edge care at @CleClinicUro as technology evolves and integrates into our practices! Highly recommend hearing from this tremendous surgeon, person, and thinker who I am lucky to call a partner! @NCSAUA #NCSAUA26 @AmerUrological

See you all at the amazing SP symposium next week! @CleClinicUro @drjkaouk

🚨 Not all Gleason pattern 4 is created equal. Quantification alone may not be enough. Reporting Crib/IDC adds important prognostic value. 🔍 We explore this in our latest Letter to the Editor @EurUrolOncol @CleClinicUro @JaneNguyen44 @ZSchwen sciencedirect.com/science/ar…

Our multicentre review in Nature Reviews Urology addresses an important topic: IDC and cribriform #ProstateCancer - aggressive patterns often missed on biopsy, with major implications for risk stratification and treatment. rdcu.be/27xcFzpbzLPa

Fantastic overview of cribriform and IDC prostate cancer by our very own @ruimmbernardino Congrats 🎉 @CleClinicUro @ricautor @drjkaouk @JaneNguyen44

Beyond the stage, dialogue continues! Moderators, speakers and GUPS leaders came together to exchange ideas, share perspectives, and strengthen connections. #GUPS

Join us for our next Distinguished Lecture Series session featuring Dr. Jesse K. McKenney Topic: Spindle Cell Lesions of the Genitourinary Tract Moderators:Dr. Emily Chan @chemily7, Dr. Rohit Mehra @drmehrarohit Nov 5, 12 PM Eastern time Register here: us02web.zoom.us/webinar/regi…

Our pathologists guide the way! @therapy_focal meeting @dr_coops highlights the blockbuster work of @JaneNguyen44 @ClevelandClinic showing that path solidly predicts outcomes in prostate cancer. Zero deaths or mets after decades of follow up in the setting of favorable histology!